Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the results from a secondary analysis of the QuANTUM-First trial (NCT02668653), in which a PCR-NGS assay was used to assess FLT3-ITD-specific measurable residual disease (MRD) clearance in patients treated with quizartinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
